Ellard R, Ahmed A, Shah R, Bewley A
Department of General Medicine, Whipps Cross Hospital, London, UK.
Clin Exp Dermatol. 2014 Jul;39(5):624-7. doi: 10.1111/ced.12351.
A 53-year-old man took his own life while receiving biological therapy with the tumour necrosis factor-α inhibitor adalimumab for severe psoriasis. The patient had a psychiatric history and a 32-year history of variable unstable psoriasis. Reported suicide in patients with psoriasis receiving adalimumab is rare (only one other reported case). It is important, however, to recognize the effects of skin disease on the mental health of vulnerable patients receiving biological agents. Patients will benefit from a more holistic approach that includes both dermatological and psychological assessment and treatment.
一名53岁男性在接受肿瘤坏死因子-α抑制剂阿达木单抗治疗严重银屑病的生物治疗期间自杀。该患者有精神病史，患不稳定型银屑病32年。接受阿达木单抗治疗的银屑病患者报告自杀情况罕见（仅另有一例报告病例）。然而，认识到皮肤病对接受生物制剂治疗的脆弱患者心理健康的影响很重要。患者将受益于更全面的方法，包括皮肤科和心理评估与治疗。
